Abeona Therapeutics
ABEO
104 hedge funds and large institutions have $444M invested in Abeona Therapeutics in 2018 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 34 increasing their positions, 24 reducing their positions, and 8 closing their positions.
163% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 8
42% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 24
13% more funds holding
Funds holding: 92 → 104 (+12)
8% more call options, than puts
Call options by funds: $2.64M | Put options by funds: $2.44M
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.19% less ownership
Funds ownership: 3.09% → 2.9% (-0.19%)
24% less capital invested
Capital invested by funds: $585M → $444M (-$140M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$11M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$4.24M |
| 3 |
NC
Nexthera Capital
New York
|
+$3.17M |
| 4 |
PA
Perceptive Advisors
New York
|
+$2.57M |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$1.61M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
-$25.2M |
| 2 |
State Street
Boston,
Massachusetts
|
-$12.5M |
| 3 |
PC
PointState Capital
New York
|
-$9.21M |
| 4 |
Millennium Management
New York
|
-$4.09M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$3.9M |
ABEO Hedge Fund Activity: Q3 2018 in Review
104 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Abeona Therapeutics (ABEO) for Q3 2018, worth a combined $444M — down 24% from $585M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new ABEO positions and 8 closed out — a net gain of 13 holders — while 34 added to existing stakes and 24 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $11M. The largest seller was Viking Global Investors, cutting an estimated $25.2M.
- 104 institutional investors held Abeona Therapeutics (ABEO) as of Q3 2018, up from 92 in Q2 2018.
- Funds reported $444M of Abeona Therapeutics stock for Q3 2018, down 24% quarter-over-quarter.
- 21 funds opened new Abeona Therapeutics positions in Q3 2018 and 8 closed out, a net change of +13 holders.
- The largest Abeona Therapeutics buyer in Q3 2018 was Wellington Management Group, an estimated $11M added.
- The largest Abeona Therapeutics seller in Q3 2018 was Viking Global Investors, an estimated $25.2M sold.
Based on aggregated 13F filings for Q3 2018.